title: Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
authors.affiliation: Baylor University Medical Center, Dallas, Texas.
authors.forename: G B
authors.initials: GB
authors.lastname: Klintmalm
authors.forename: R
authors.initials: R
authors.lastname: Goldstein
authors.forename: T
authors.initials: T
authors.lastname: Gonwa
authors.forename: R H
authors.initials: RH
authors.lastname: Wiesner
authors.forename: R A
authors.initials: RA
authors.lastname: Krom
authors.forename: B W
authors.initials: BW
authors.lastname: Shaw
authors.forename: R
authors.initials: R
authors.lastname: Stratta
authors.forename: N L
authors.initials: NL
authors.lastname: Ascher
authors.forename: J W
authors.initials: JW
authors.lastname: Roberts
authors.forename: J
authors.initials: J
authors.lastname: Lake
mesh_terms: D000208:Acute Disease; D000367:Age Factors; D000704:Analysis of Variance; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D012727:Sex Characteristics; D016019:Survival Analysis; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus